Charles Matine - 09 Jun 2023 Form 4 Insider Report for Bionik Laboratories Corp.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 09 Jun 2023
Net transaction value: +$108,333
SEC form: 4
Accepted by SEC: 21 Jun 2023, 10:57:58 UTC
Source filing: View source filing
Reporting owner signature: /s/ Charles Matine

Key filing fact

Charles Matine filed Form 4 for Bionik Laboratories Corp. on 21 Jun 2023.

Key facts

This page summarizes Charles Matine's Form 4 filing for Bionik Laboratories Corp..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 21 Jun 2023, 10:57.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: +$108,333.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BNKL transaction

Common Stock, par value $0.001 per share

Purchase

Transaction value: $108,333
Shares: +180,555
Change %: +683%
Price: $0.6000
Shares after: 206,985
Date: 09 Jun 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The reporting person acquired the shares of common stock in lieu of cash payment for $108,333 in accrued and unpaid fees relating to reporting person's services as a director of the Issuer.